Cumberland Pharmaceuticals Inc. — 2014 Form 10-K Summary
Business context and reporting period
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products primarily for hospital acute care and gastroenterology. Its marketed portfolio comprised Acetadote, Caldolor, Kristalose, Omeclamox-Pak and Vaprisol; Hepatoren and Boxaban were Phase II candidates. The filing covers the fiscal year ended December 31, 2014, with quarterly information included for the fourth quarter.
The company had 85 full-time employees at year-end and used third parties for manufacturing, packaging, logistics and distribution. Its common stock trades on Nasdaq under the symbol CPIX.
Financial performance and key metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Net revenues | $36.9 million | $32.0 million | 15.2% increase |
| Operating income (loss) | $3.6 million | $(3.8) million | $7.4 million improvement |
| Net income (loss) attributable to common shareholders | $2.4 million | $(2.1) million | Returned to profitability |
| Diluted EPS | $0.14 | $(0.11) | Improved |
| Cash flow from operations | $6.7 million | $0.7 million | Improved by $5.9 million |
Net product revenue was $36.7 million, while other revenue was $0.2 million. Approximate 2014 margins were 86.3% gross margin, 9.6% operating margin and 6.6% net margin. Cost of products sold declined to 13.7% of revenue from 17.0%, partly due to product mix, higher pricing and the absence of the $0.9 million inventory write-down recorded in 2013.
| 2014 product revenue | Revenue | Year-over-year change |
|---|---|---|
| Kristalose | $14.9 million | 63.8% increase |
| Acetadote | $11.9 million | $6.9 million decrease |
| Omeclamox-Pak | $4.1 million | $3.1 million increase |
| Vaprisol | $3.0 million | New contribution in 2014 |
| Caldolor | $2.7 million | 30.2% increase |
Cash, cash equivalents and marketable securities totaled $54.7 million at December 31, 2014, compared with $54.9 million at year-end 2013. Cash and cash equivalents were $39.9 million, marketable securities were $14.8 million, and working capital was $57.1 million. The current ratio was 5.2x, down from 9.1x.
The company had no borrowings outstanding at year-end. Its new SunTrust revolving credit facility provides an initial $12.0 million commitment, expandable to $20.0 million, through June 2017. Borrowings are collateralized by substantially all assets and bear interest at LIBOR plus a spread of 1.0% to 2.85%. The company was in compliance with its covenants.
Total assets were $95.4 million, including $21.6 million of net intangible assets. Total liabilities were $14.7 million and total equity was $80.8 million. The company repurchased 881,810 shares for approximately $4.3 million during 2014 and paid no dividends.
Material changes versus the prior comparable period
- Revenue increased 15.2%, driven by Kristalose growth, the full-year impact of Omeclamox-Pak and the addition of Vaprisol.
- Kristalose became the largest-selling product after a repositioning program, price increase, enhanced patient coupon program and expanded managed-care coverage.
- Acetadote revenue declined materially because of generic competition; Authorized Generic revenue fell to $5.8 million from $9.2 million.
- Vaprisol was acquired from Astellas in February 2014 for an upfront payment of $2.0 million and generated approximately $3.0 million of 2014 revenue. Up to $2.0 million of additional consideration could become payable based on first-year sales.
- Operating results returned to profitability, reflecting higher revenue, lower research and development spending, lower general and administrative expense and reduced product costs. Amortization increased by $0.7 million because of acquired product rights and capitalized patent costs.
- Research and development expense declined 39.6% to $3.4 million following the completion of Caldolor clinical studies in 2013.
- The company invested $1.0 million in CET and received approximately $1.0 million from Gloria Pharmaceuticals; Cumberland’s ownership of CET declined from 85% to 80%.
- Cash flow from operations increased substantially, but total cash declined by $1.0 million after Vaprisol acquisition payments, intangible asset investments, marketable-security purchases and share repurchases.
Outlook, commentary, risks and unusual items
Management’s strategy is to maximize existing brands, expand internationally, acquire additional marketed or late-stage products, pursue label expansions and develop early-stage candidates through CET. Management stated that internally generated cash flow and available credit were expected to fund existing debt service, internal growth and capital expenditures.
- Hepatoren remained in a 64-patient Phase II study for hepatorenal syndrome. Type II enrollment was completed in 2014, and preliminary results indicated tolerability and a possible urine-output signal at higher doses. Further development was planned, but regulatory approval and commercialization remain uncertain.
- Boxaban entered Phase II development for aspirin-exacerbated respiratory disease after the FDA cleared an IND amendment. The filing does not provide an expected approval date or commercialization forecast.
- Acetadote remains subject to generic competition and multiple Paragraph IV patent challenges. The Mylan infringement matter was pending, and new challenges from Aurobindo and Zydus were identified around the filing date. The company intends to defend its patents, but outcomes are uncertain.
- The company relies on third-party manufacturers and faces supply-transfer, quality, capacity and single-source risks. A new U.S. Acetadote manufacturer was being qualified, and Caldolor manufacturing had been transferred to new suppliers.
- Omeclamox-Pak experienced a temporary inventory shortage during 2014. Kristalose depends on a key Italian active-ingredient supplier, and inventory expiration risk remains relevant, particularly for Caldolor.
- Revenue recognition depends materially on estimates for rebates, chargebacks, returns and service fees. Related accrued liabilities increased to $5.2 million from $2.4 million.
- Four customers represented at least 10% of gross revenue each, and the four customers collectively represented 91.1% of accounts receivable at year-end, indicating significant customer concentration.
- Contractual commitments included operating leases of $2.3 million, Kristalose payments based on future sales, potential Omeclamox-Pak milestone payments of up to $3.0 million and potential Vaprisol consideration of up to $2.0 million.
- The company was involved in Acetadote patent litigation and arbitration with Mylan regarding manufacturing and supply obligations. Management stated that matters other than the Acetadote patent issue were not expected to materially affect consolidated results.
KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2014.
Most important facts for investors to verify
- Whether Kristalose growth and the contributions from Vaprisol and Omeclamox-Pak can offset continuing Acetadote erosion.
- The status and potential economic impact of Acetadote patent litigation, including the Mylan, Aurobindo and Zydus challenges.
- Actual first-year Vaprisol sales and whether the contingent consideration of up to $2.0 million becomes payable.
- Supply continuity, inventory aging and expiration exposure for Caldolor, Acetadote, Kristalose and Omeclamox-Pak.
- Whether Hepatoren and Boxaban produce clinically and regulatorily sufficient results to justify additional development spending.
- The reasonableness of revenue accruals for rebates, returns, chargebacks and service fees, which totaled $5.2 million at year-end.
- The company’s customer concentration, reliance on third-party manufacturers and continued use of share repurchases while maintaining substantial liquidity.